Fedratinib Earns Priority Review Status for Myelofibrosis From FDA - https://t.co/aKeLjhHz98 Managed Markets Network https://t.co/nyLOUqOWKt
— IDRO (@IDROOhio) March 8, 2019
from Twitter https://twitter.com/IDROOhio
March 07, 2019 at 10:32PM
Friday, March 8, 2019
Fedratinib Earns Priority Review Status for Myelofibrosis From FDA - https://t.co/aKeLjhHz98 Managed Markets Network https://t.co/nyLOUqOWKt
from Twitter https://twitter.com/IDROOhio
March 07, 2019 at 10:32PM
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment